# A Study to Evaluate the Safety and Pharmacokinetic of Recombinant Human Coagulation Factor VIII ，Fc Fusion Protein for Injection

> **NCT05251090** · PHASE1 · COMPLETED · sponsor: **Jiangsu Gensciences lnc.** · enrollment: 13 (actual)

## Conditions studied

- Hemophilia A

## Interventions

- **DRUG:** ADVATE
- **DRUG:** FRSW107

## Key facts

- **NCT ID:** NCT05251090
- **Lead sponsor:** Jiangsu Gensciences lnc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-06-16
- **Primary completion:** 2021-11-15
- **Final completion:** 2022-05-09
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2023-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05251090

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05251090, "A Study to Evaluate the Safety and Pharmacokinetic of Recombinant Human Coagulation Factor VIII ，Fc Fusion Protein for Injection". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT05251090. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*